Compare Pfizer Inc (PFE) vs Raytheon Technologies Corp (RTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Raytheon Technologies Corp — how do they compare? Pfizer Inc trades at $24.91 (market cap $142.14B), while Raytheon Technologies Corp trades at $194.53 (market cap $260.81B). The key difference: Raytheon Technologies Corp is the larger of the two by market cap, and Pfizer Inc pays the higher dividend (6.9%). Which is the better fit depends on your goals.
| PFE | RTX | |
|---|---|---|
Market Cap | $142.14B | $260.81B |
Volume | 29,869,932 | — |
Sector | Health | Industrials |
52-Week High | $28.56 | $212.16 |
52-Week Low | $23.29 | $149.17 |
Enterprise Value | $192.80B | $292.93B |
Dividend Yield | 6.9% | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $24.83, up 0.32% today, with a neutral technical signal and bearish moving averages. The company reported revenue of $62.58B in 2025, with a net income margin of 11.83%, and has beaten EPS estimates for the last three quarters. Recent news highlights pipeline developments in oncology and obesity, with a consensus analyst price target of $28.25.
PFE offers a stable dividend and trades below analyst targets, but faces headwinds from patent expirations and volatile cash flows. The stock presents value with a P/E of 19.04, though growth depends on successful drug launches and navigating post-COVID revenue normalization.
RTX trades at $194.88, up 0.23% today, with a bullish technical signal and strong analyst support. Recent contract wins, including a $515 million Navy radar award (PRNewsWire, June 3, 2026), and expanding manufacturing capacity in Poland highlight growth momentum. The company has beaten earnings estimates in recent quarters, with Q1 2026 EPS of $1.78 surpassing the $1.51 forecast. Revenue growth accelerated to $88.6 billion in 2025, driving net income to $6.73 billion.
The outlook is positive, supported by robust defense spending and operational execution. However, a high P/E ratio of 36.34 suggests premium valuation, while rising long-term debt poses a financial risk. The stock offers a dividend yield of approximately 1.5%, with the next payment of $0.73 scheduled for September 3, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →
